Macrocure Says Phase III Clinical Trial of CureXcell in Venous Leg Ulcers Not Expected to Meet Primary Endpoint.

By: via Benzinga
Macrocure Ltd. (NASDAQ: MCUR) announced Wednesday, that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.